Avastin European Medicines Agency

Avastin is a medicine registered by Medsafe but not funded by PHARMAC, so you will need to pay for it Roche New Zealand has a FRVW VKDUH programme for

The goal of Avastin treatment is to prevent further loss of vision Although some patients regain vision, the medication may not restore vision that was already

avastin Avastin is part of a class of drugs that block the growth of abnormal blood vessels, which is the cause of wet age-related macular degeneration Avastin

avastin Worldwide patients have been having Avastin eye injections since 2007 More recently a newer drug called Aflibercept or Eyelea has also been licensed for AMD